Gastrointestinal stromal tumors of the rectum

被引：0

作者：

Reichardt, Peter ^{[1
,4
]}

Kolligs, Frank T. ^{[2
]}

Steinbach, Marcus ^{[3
]}

机构：

[1] Helios Klinikum Berlin Buch GmbH, Med Sch Berlin, Klin Onkol & Palliat Med, Berlin, Germany

[2] Helios Klinikum Berlin Buch, Med Sch Berlin, Klin Innere Med & Gastroenterol, Interdisziplinares Endoskopiezentrum, Berlin, Germany

[3] Helios Klinikum Berlin Buch, Klin Allgemein Viszeral & Onkol Chirurg, Berlin, Germany

[4] Helios Klinikum Berlin Buch GmbH, Med Sch Berlin, Klin Onkol & Palliat Med, Schwanebecker Chaussee 50, D-13125 Berlin, Germany

来源：

COLOPROCTOLOGY | 2024年 / 46卷 / 01期

关键词：

Mesenchymal neoplasms; Submucosal tumor; Mesenchymal tumor; Surgery; Drug treatment; IMATINIB MESYLATE; PHASE-III; EFFICACY; SAFETY; TRIAL; METAANALYSIS; MULTICENTER; RISK;

D O I：

10.1007/s00053-023-00757-7

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Gastrointestinal stromal tumors (GIST) are rare tumors that can arise in the whole gastrointestinal tract and belong to the group of soft tissue sarcomas. They represent less than 1% of all gastrointestinal tumors and 90% of GISTs are located in the stomach and small intestine. Only 5% are found in the rectum and are therefore a rarity. In localized stages surgical resection is carried out and depending on the size and risk constellation, neoadjuvant or adjuvant systemic therapy is recommended. A mutational analysis on the tumor tissue is of central importance for treatment planning. Imatinib at a dose of 400 mg per day is the gold standard for advanced stages of disease. In patients with an exon 9 mutation the recommended dose is 800 mg imatinib per day. In imatinib-refractory disease or intolerance to imatinib, sunitinib, regorafenib, and ripretinib are further treatment options.

引用

页码：22 / 29

页数：8

共 22 条

[1] Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT [J].

Blanke, Charles D. ;

Demetri, George D. ;

von Mehren, Margaret ;

Heinrich, Michael C. ;

Eisenberg, Burton ;

Fletcher, Jonathan A. ;

Corless, Christopher L. ;

Fletcher, Christopher D. M. ;

Roberts, Peter J. ;

Heinz, Daniela ;

Wehre, Elisabeth ;

Nikolova, Zariana ;

Joensuu, Heikki .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :620-625

[2]

Blay JY, 2007, J CLIN ONCOL, V25, P1107, DOI 10.1200/JCO.2006.09.0183

[3] Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial [J].

Blay, Jean-Yves ;

Serrano, Cesar ;

Heinrich, Michael C. ;

Zalcberg, John ;

Bauer, Sebastian ;

Gelderblom, Hans ;

Schoffski, Patrick ;

Jones, Robin L. ;

Attia, Steven ;

D'Amato, Gina ;

Chi, Ping ;

Reichardt, Peter ;

Meade, Julie ;

Shi, Kelvin ;

Ruiz-Soto, Rodrigo ;

George, Suzanne ;

von Mehren, Margaret .

LANCET ONCOLOGY, 2020, 21 (07) :923-934

[4] Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Casali, P. G. ;

Blay, J. Y. ;

Abecassis, N. ;

Bajpai, J. ;

Bauer, S. ;

Biagini, R. ;

Bielack, S. ;

Bonvalot, S. ;

Boukovinas, I ;

Bovee, J. V. M. G. ;

Boye, K. ;

Brodowicz, T. ;

Buonadonna, A. ;

De Alava, E. ;

Dei Tos, A. P. ;

Del Muro, X. G. ;

Dufresne, A. ;

Eriksson, M. ;

Fedenko, A. ;

Ferraresi, V ;

Ferrari, A. ;

Frezza, A. M. ;

Gasperoni, S. ;

Gelderblom, H. ;

Gouin, F. ;

Grignani, G. ;

Haas, R. ;

Hassan, A. B. ;

Hindi, N. ;

Hohenberger, P. ;

Joensuu, H. ;

Jones, R. L. ;

Jungels, C. ;

Jutte, P. ;

Kasper, B. ;

Kawai, A. ;

Kopeckova, K. ;

Krakorova, D. A. ;

Le Cesne, A. ;

Le Grange, F. ;

Legius, E. ;

Leithner, A. ;

Lopez-Pousa, A. ;

Martin-Broto, J. ;

Merimsky, O. ;

Messiou, C. ;

Miah, A. B. ;

Mir, O. ;

Montemurro, M. ;

Morosi, C. .

ANNALS OF ONCOLOGY, 2022, 33 (01) :20-33

[5] Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels [J].

Casali, Paolo G. ;

Zalcberg, John ;

Le Cesne, Axel ;

Reichardt, Peter ;

Blay, Jean-Yves ;

Lindner, Lars H. ;

Judson, Ian R. ;

Schoffski, Patrick ;

Leyvraz, Serge ;

Italiano, Antoine ;

Grunwald, Viktor ;

Pousa, Antonio Lopez ;

Kotasek, Dusan ;

Sleijfer, Stefan ;

Kerst, Jan M. ;

Rutkowski, Piotr ;

Fumagalli, Elena ;

Hogendoorn, Pancras ;

Litiere, Saskia ;

Marreaud, Sandrine ;

van der Graaf, Winette ;

Gronchi, Alessandro ;

Verweij, Jaap .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (15) :1713-+

[6] Endoscopic management of gastrointestinal stromal tumors [J].

Chandrasekhara V. ;

Ginsberg G.G. .

Current Gastroenterology Reports, 2011, 13 (6) :532-539

[7] Systematic review and meta-analysis of safety and efficacy of laparoscopic resection for gastrointestinal stromal tumors of the stomach [J].

Chen, Ke ;

Zhou, Yu-Cheng ;

Mou, Yi-Ping ;

Xu, Xiao-Wu ;

Jin, Wei-Wei ;

Ajoodhea, Harsha .

SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2015, 29 (02) :355-367

[8] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].

Demetri, GD ;

von Mehren, M ;

Blanke, CD ;

Van den Abbeele, AD ;

Eisenberg, B ;

Roberts, PJ ;

Heinrich, MC ;

Tuveson, DA ;

Singer, S ;

Janicek, M ;

Fletcher, JA ;

Silverman, SG ;

Silberman, SL ;

Capdeville, R ;

Kiese, B ;

Peng, B ;

Dimitrijevic, S ;

Druker, BJ ;

Corless, C ;

Fletcher, CDM ;

Joensuu, H .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480

[9] Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial [J].

Demetri, George D. ;

van Oosterom, Allan T. ;

Garrett, Christopher R. ;

Blackstein, Martin E. ;

Shah, Manisha H. ;

Verweij, Jaap ;

McArthur, Grant ;

Judson, Ian R. ;

Heinrich, Michael C. ;

Morgan, Jeffrey A. ;

Desai, Jayesh ;

D Fletcher, Christopher ;

George, Suzanne ;

Bello, Carlo L. ;

Huang, Xin ;

Baum, Charles M. ;

Casali, Paolo G. .

LANCET, 2006, 368 (9544) :1329-1338

[10] Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial [J].

Demetri, George D. ;

Reichardt, Peter ;

Kang, Yoon-Koo ;

Blay, Jean-Yves ;

Rutkowski, Piotr ;

Gelderblom, Hans ;

Hohenberger, Peter ;

Leahy, Michael ;

von Mehren, Margaret ;

Joensuu, Heikki ;

Badalamenti, Giuseppe ;

Blackstein, Martin ;

Le Cesne, Axel ;

Schoffski, Patrick ;

Maki, Robert G. ;

Bauer, Sebastian ;

Binh Bui Nguyen ;

Xu, Jianming ;

Nishida, Toshirou ;

Chung, John ;

Kappeler, Christian ;

Kuss, Iris ;

Laurent, Dirk ;

Casali, Paolo G. .

LANCET, 2013, 381 (9863) :295-302

← 1 2 3 →